Share Price and Basic Stock Data
Last Updated: December 17, 2025, 10:44 pm
| PEG Ratio | 1.51 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambar Protein Industries Ltd, operating in the edible oils and solvent extraction sector, has shown a steady revenue trajectory over recent years. For the financial year ending March 2025, the company reported sales of ₹421 Cr, a notable increase from ₹345 Cr in the previous year. This growth reflects the company’s ability to navigate market challenges and capitalize on demand in the edible oils segment. However, the revenue figures have exhibited fluctuations on a quarterly basis, with the June 2023 sales reaching ₹93.22 Cr, followed by a dip to ₹68.61 Cr in September 2023, only to recover to ₹85.72 Cr in December 2023. Such volatility may be indicative of seasonal demand patterns or operational challenges. Overall, the reported TTM revenue of ₹446 Cr suggests that while Ambar is on a growth path, maintaining consistency will be crucial for long-term investor confidence.
Profitability and Efficiency Metrics
Profitability metrics for Ambar Protein Industries present a mixed picture. The company recorded a net profit of ₹10 Cr for FY 2025, up from ₹3 Cr the previous year, translating to an impressive earnings per share (EPS) of ₹16.78. However, the operating profit margin (OPM) has been relatively modest, at 4% for FY 2025, compared to a more robust 2% in FY 2024. This suggests that while Ambar is generating profits, the efficiency of its operations in converting revenue to profit could be improved. The interest coverage ratio stood at a healthy 7.32x, indicating that the company comfortably meets its interest obligations. Yet, with an OPM of just 4%, the challenge remains to enhance operational efficiency to sustain profitability, especially in a competitive industry where margins are often thin.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ambar Protein Industries appears relatively robust, characterized by total borrowings of ₹23 Cr against reserves of ₹32 Cr. This positions the company with a solid equity base, reflected in a return on equity (ROE) of 32.3%, which is significantly above industry norms. The current ratio of 1.45 suggests adequate liquidity to cover short-term obligations, although the quick ratio of 0.83 indicates potential concerns about immediate liquidity. The company’s debt-to-equity ratio of 0.74x shows a balanced approach to leverage, but investors should be cautious about the potential risks associated with high leverage in uncertain market conditions. Overall, while the financial ratios indicate a strong foundation, attention must be paid to managing debt levels and ensuring liquidity to support operational needs.
Shareholding Pattern and Investor Confidence
Ambar Protein Industries has a concentrated shareholding structure, with promoters holding 71.48% of the company as of September 2025. This significant stake suggests a strong alignment of interests between management and shareholders, which can be reassuring for investors. The public shareholding stands at 28.51%, indicating a relatively diverse investor base, though institutional interest appears absent with no foreign or domestic institutional investors reported. The number of shareholders has increased to 3,177, reflecting growing interest in the company. However, the absence of institutional backing could pose risks, as institutional investors often provide stability and confidence during market fluctuations. As the company continues to grow, attracting institutional investment will be essential to bolster its credibility and support its long-term strategies.
Outlook, Risks, and Final Insight
The outlook for Ambar Protein Industries is a blend of potential and challenges. On one hand, the company’s steady revenue growth and strong profitability ratios suggest a positive trajectory, with increasing interest from retail investors evident in its rising shareholder count. However, the volatility in quarterly sales and relatively low operating margins highlight operational challenges that need addressing. Risks such as fluctuating raw material prices, potential regulatory changes in the edible oils sector, and the absence of institutional investors may impact future performance. For investors, it will be essential to monitor how effectively the company can manage these risks while capitalizing on growth opportunities. A focus on enhancing operational efficiency and attracting institutional interest could be pivotal in shaping Ambar’s path forward. As always, prudent investors should weigh these factors carefully before making decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 488 Cr. | 367 | 610/320 | 13.4 | 107 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 92.2 Cr. | 7.07 | 10.3/3.87 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 310 Cr. | 1.65 | 3.84/1.52 | 217 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 67.0 Cr. | 2.81 | 3.99/1.45 | 26.1 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 4,859 Cr. | 1,736 | 3,633/321 | 2,394 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 10,457.93 Cr | 192.42 | 177.34 | 37.26 | 0.18% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84.38 | 75.77 | 94.92 | 90.00 | 93.22 | 68.61 | 85.72 | 89.51 | 93.04 | 88.95 | 111.82 | 127.81 | 117.27 |
| Expenses | 81.92 | 74.30 | 92.42 | 89.17 | 90.62 | 67.04 | 81.90 | 90.26 | 90.10 | 84.72 | 107.00 | 124.02 | 115.13 |
| Operating Profit | 2.46 | 1.47 | 2.50 | 0.83 | 2.60 | 1.57 | 3.82 | -0.75 | 2.94 | 4.23 | 4.82 | 3.79 | 2.14 |
| OPM % | 2.92% | 1.94% | 2.63% | 0.92% | 2.79% | 2.29% | 4.46% | -0.84% | 3.16% | 4.76% | 4.31% | 2.97% | 1.82% |
| Other Income | 0.11 | 0.13 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.31 | 0.22 | 0.22 | 0.19 | 0.20 | 0.19 |
| Interest | 0.62 | 0.66 | 0.65 | 0.60 | 0.64 | 0.63 | 0.69 | 0.50 | 0.56 | 0.56 | 0.57 | 0.58 | 0.53 |
| Depreciation | 0.32 | 0.32 | 0.32 | 0.31 | 0.33 | 0.26 | 0.39 | 0.34 | 0.32 | 0.32 | 0.46 | 0.21 | 0.33 |
| Profit before tax | 1.63 | 0.62 | 1.65 | 0.06 | 1.75 | 0.80 | 2.86 | -1.28 | 2.28 | 3.57 | 3.98 | 3.20 | 1.47 |
| Tax % | 17.79% | 27.42% | 37.58% | 116.67% | 27.43% | 2.50% | 45.10% | -64.84% | 24.56% | 24.65% | 29.15% | 22.19% | 48.98% |
| Net Profit | 1.34 | 0.46 | 1.03 | -0.02 | 1.26 | 0.78 | 1.56 | -0.45 | 1.72 | 2.69 | 2.82 | 2.48 | 0.75 |
| EPS in Rs | 2.33 | 0.80 | 1.79 | -0.03 | 2.19 | 1.36 | 2.71 | -0.78 | 2.99 | 4.68 | 4.90 | 4.31 | 1.30 |
Last Updated: August 19, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 117.27 Cr.. The value appears to be declining and may need further review. It has decreased from 127.81 Cr. (Mar 2025) to 117.27 Cr., marking a decrease of 10.54 Cr..
- For Expenses, as of Jun 2025, the value is 115.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.02 Cr. (Mar 2025) to 115.13 Cr., marking a decrease of 8.89 Cr..
- For Operating Profit, as of Jun 2025, the value is 2.14 Cr.. The value appears to be declining and may need further review. It has decreased from 3.79 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 1.65 Cr..
- For OPM %, as of Jun 2025, the value is 1.82%. The value appears to be declining and may need further review. It has decreased from 2.97% (Mar 2025) to 1.82%, marking a decrease of 1.15%.
- For Other Income, as of Jun 2025, the value is 0.19 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to 0.19 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.58 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 0.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.21 Cr. (Mar 2025) to 0.33 Cr., marking an increase of 0.12 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.20 Cr. (Mar 2025) to 1.47 Cr., marking a decrease of 1.73 Cr..
- For Tax %, as of Jun 2025, the value is 48.98%. The value appears to be increasing, which may not be favorable. It has increased from 22.19% (Mar 2025) to 48.98%, marking an increase of 26.79%.
- For Net Profit, as of Jun 2025, the value is 0.75 Cr.. The value appears to be declining and may need further review. It has decreased from 2.48 Cr. (Mar 2025) to 0.75 Cr., marking a decrease of 1.73 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.30. The value appears to be declining and may need further review. It has decreased from 4.31 (Mar 2025) to 1.30, marking a decrease of 3.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 157 | 168 | 195 | 206 | 231 | 284 | 313 | 340 | 345 | 336 | 421 | 469 |
| Expenses | 159 | 155 | 167 | 193 | 203 | 227 | 278 | 305 | 330 | 338 | 328 | 406 | 455 |
| Operating Profit | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 8 | 9 | 7 | 7 | 16 | 13 |
| OPM % | 1% | 1% | 1% | 1% | 1% | 2% | 2% | 2% | 3% | 2% | 2% | 4% | 3% |
| Other Income | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 2 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 13 | 11 |
| Tax % | 0% | 0% | 36% | 2% | 27% | 28% | 55% | 13% | 25% | 29% | 24% | 26% | |
| Net Profit | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 10 | 8 |
| EPS in Rs | 0.14 | 2.70 | 1.51 | 4.19 | 3.74 | 3.53 | 2.17 | 6.00 | 7.74 | 4.89 | 5.48 | 16.78 | 13.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% | 200.00% | 33.33% | -25.00% | 0.00% | 233.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 150.00% | -100.00% | 0.00% | -50.00% | 250.00% | -166.67% | -58.33% | 25.00% | 233.33% |
Ambar Protein Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 50% |
| 3 Years: | 29% |
| TTM: | 142% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| 1 Year: | 127% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| Last Year: | 32% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | -4 | -3 | -1 | 0 | 2 | 4 | 5 | 9 | 13 | 16 | 19 | 29 | 32 |
| Borrowings | 6 | 6 | 8 | 10 | 18 | 24 | 27 | 27 | 33 | 29 | 26 | 26 | 23 |
| Other Liabilities | 5 | 4 | 5 | 7 | 5 | 19 | 11 | 8 | 12 | 11 | 11 | 10 | 10 |
| Total Liabilities | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
| Fixed Assets | 4 | 4 | 6 | 6 | 6 | 7 | 22 | 21 | 21 | 20 | 19 | 18 | 18 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 16 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8 | 9 | 12 | 17 | 19 | 31 | 27 | 29 | 44 | 42 | 42 | 51 | 52 |
| Total Assets | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
Below is a detailed analysis of the balance sheet data for Ambar Protein Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 23.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 70.00 Cr.. The value appears to be improving (decreasing). It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
Notably, the Reserves (32.00 Cr.) exceed the Borrowings (23.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -4.00 | -6.00 | -7.00 | -15.00 | -20.00 | -21.00 | -19.00 | -24.00 | -22.00 | -19.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3 | 2 | 3 | 8 | 3 | 2 | 3 | 4 | 10 | 15 | 15 | 18 |
| Inventory Days | 11 | 12 | 18 | 19 | 16 | 37 | 20 | 22 | 32 | 23 | 24 | 20 |
| Days Payable | 13 | 10 | 11 | 9 | 6 | 10 | 3 | 5 | 9 | 7 | 8 | 3 |
| Cash Conversion Cycle | 1 | 4 | 10 | 18 | 13 | 29 | 19 | 21 | 33 | 30 | 31 | 34 |
| Working Capital Days | -8 | -8 | -4 | -1 | -4 | -9 | -8 | -2 | 3 | 4 | 6 | 12 |
| ROCE % | 8% | 28% | 18% | 22% | 17% | 13% | 15% | 18% | 18% | 13% | 13% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Diluted EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Cash EPS (Rs.) | 19.06 | 7.75 | 7.11 | 9.97 | 8.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Revenue From Operations / Share (Rs.) | 733.26 | 586.19 | 600.13 | 590.87 | 544.87 |
| PBDIT / Share (Rs.) | 28.89 | 13.72 | 13.50 | 17.18 | 13.61 |
| PBIT / Share (Rs.) | 26.61 | 11.43 | 11.29 | 14.95 | 11.52 |
| PBT / Share (Rs.) | 22.66 | 7.16 | 6.88 | 10.27 | 6.92 |
| Net Profit / Share (Rs.) | 16.78 | 5.47 | 4.89 | 7.74 | 6.00 |
| PBDIT Margin (%) | 3.93 | 2.34 | 2.25 | 2.90 | 2.49 |
| PBIT Margin (%) | 3.62 | 1.95 | 1.88 | 2.53 | 2.11 |
| PBT Margin (%) | 3.09 | 1.22 | 1.14 | 1.73 | 1.27 |
| Net Profit Margin (%) | 2.28 | 0.93 | 0.81 | 1.30 | 1.10 |
| Return on Networth / Equity (%) | 27.79 | 12.54 | 12.83 | 23.30 | 23.54 |
| Return on Capital Employeed (%) | 41.06 | 23.61 | 24.19 | 34.46 | 30.62 |
| Return On Assets (%) | 13.68 | 5.12 | 4.51 | 6.93 | 6.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.07 | 0.14 | 0.24 |
| Total Debt / Equity (X) | 0.74 | 1.02 | 1.34 | 1.72 | 1.86 |
| Asset Turnover Ratio (%) | 6.39 | 5.45 | 5.46 | 5.94 | 6.29 |
| Current Ratio (X) | 1.45 | 1.21 | 1.19 | 1.11 | 1.00 |
| Quick Ratio (X) | 0.83 | 0.61 | 0.63 | 0.42 | 0.39 |
| Inventory Turnover Ratio (X) | 20.84 | 16.08 | 13.93 | 14.65 | 18.92 |
| Interest Coverage Ratio (X) | 7.32 | 3.21 | 3.07 | 3.67 | 2.96 |
| Interest Coverage Ratio (Post Tax) (X) | 5.26 | 2.28 | 2.11 | 2.65 | 2.30 |
| Enterprise Value (Cr.) | 141.53 | 108.01 | 151.38 | 48.68 | 29.74 |
| EV / Net Operating Revenue (X) | 0.33 | 0.32 | 0.43 | 0.14 | 0.09 |
| EV / EBITDA (X) | 8.52 | 13.69 | 19.50 | 4.93 | 3.80 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| Price / BV (X) | 3.36 | 3.34 | 5.62 | 0.89 | 0.27 |
| Price / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| EarningsYield | 0.08 | 0.03 | 0.02 | 0.26 | 0.85 |
After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
- For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
- For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
- For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.84. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 20.84, marking an increase of 4.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambar Protein Industries Ltd:
- Net Profit Margin: 2.28%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 41.06% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.79% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19 (Industry average Stock P/E: 177.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.74
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.28%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Block No. 351p2, 353p2 and 358, Panchratna Estate, Ahmedabad District Gujarat 382213 | ambarinv@gmail.com http://www.ambarprotein.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep C Khetani | Managing Director |
| Mr. Jayprakash J Vachhani | Whole Time Director |
| Mr. Shirishkumar D Patel | Director |
| Mr. Bharatbhai D Patel | Director |
| Mr. Dashrathbhai A Patel | Director |
| Mrs. Shobhanaben J Vachhani | Director |
| Mr. Gangaram Bhanjibhai Patel | Independent Director |
| Mr. Yogen Pranjivandas Patel | Independent Director |
| Mr. Narottam Chaturdas Tanna | Independent Director |
FAQ
What is the intrinsic value of Ambar Protein Industries Ltd?
Ambar Protein Industries Ltd's intrinsic value (as of 18 December 2025) is 326.51 which is 22.75% higher the current market price of 266.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 153 Cr. market cap, FY2025-2026 high/low of 433/168, reserves of ₹32 Cr, and liabilities of 70 Cr.
What is the Market Cap of Ambar Protein Industries Ltd?
The Market Cap of Ambar Protein Industries Ltd is 153 Cr..
What is the current Stock Price of Ambar Protein Industries Ltd as on 18 December 2025?
The current stock price of Ambar Protein Industries Ltd as on 18 December 2025 is 266.
What is the High / Low of Ambar Protein Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambar Protein Industries Ltd stocks is 433/168.
What is the Stock P/E of Ambar Protein Industries Ltd?
The Stock P/E of Ambar Protein Industries Ltd is 19.0.
What is the Book Value of Ambar Protein Industries Ltd?
The Book Value of Ambar Protein Industries Ltd is 65.2.
What is the Dividend Yield of Ambar Protein Industries Ltd?
The Dividend Yield of Ambar Protein Industries Ltd is 0.00 %.
What is the ROCE of Ambar Protein Industries Ltd?
The ROCE of Ambar Protein Industries Ltd is 27.5 %.
What is the ROE of Ambar Protein Industries Ltd?
The ROE of Ambar Protein Industries Ltd is 32.3 %.
What is the Face Value of Ambar Protein Industries Ltd?
The Face Value of Ambar Protein Industries Ltd is 10.0.